Hover a dot or row, or tab through the dots · bars scaled to the largest round ($709M)
Form D offerings
One line per offering, amendments folded in, newest first
Form D offerings
File
First filed
Latest
Sought
Sold
Investors
Exemptions
021-186617
First filed2012-11-07
Latest2012-11-07
Sought$43.9M
Sold$43.9M
Investors26
Exemptions506
021-185455
First filed2012-10-12
Latest2012-10-12
Sought$709M
Sold$709M
Investors60
Exemptions506
Who backs Par Pharmaceutical Holdings, Inc., inferred from co-filings, and every Form D as filedSee plans
People
Named in Item 3 of its latest Form D, filed 2012-11-07
Related persons
Name
Relationship
PATRICK G. LEPORE
RelationshipExecutive Officer, Director
THOMAS J. HAUGHEY
RelationshipExecutive Officer
PAUL V. CAMPANELLI
RelationshipExecutive Officer, Director
MICHAEL TROPIANO
RelationshipExecutive Officer
TODD SISITSKY
RelationshipDirector
JEFF RHODES
RelationshipDirector
SHARAD MANSUKANI
RelationshipDirector
BARRY J. GILMAN
RelationshipExecutive Officer
Facts
As its latest Form D states them
Industry
Other
State
New York (NY)
Exemptions
Rule 506
First filed
2012-10-12
Latest filing
2012-11-07
Who backs Par Pharmaceutical Holdings, Inc.
Form D names a startup's officers and directors, not its investors. The dashboard infers them — the venture funds whose own filings and people overlap this company's rounds — and lays every Form D and amendment it filed beside the totals above.
Inferred investors — the funds and firms behind it, from co-filings and shared people
Every Form D and amendment as filed, with what each one stated
Its rounds in sequence: the gap between them and whether they grew
Everyone its filings name, linked to their other companies, with its addresses and phone numbers
Part of the Venture plan — $140/mo at launch pricing ($350 list)